The pan-deacetylase inhibitor panobinostat induces cell death and synergizes with everolimus in Hodgkin lymphoma cell lines

Cytotoxic activity of the histone deacetylase inhibitor panobinostat (LBH589) in anaplastic thyroid cancer in vitro and in vivo

(2011) Maria Graziella Catalano et al.   INTERNATIONAL JOURNAL OF CANCER

Targeting Glucose Metabolism

(2010) Brijesh M. Madhok et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

The pan-DAC inhibitor LBH589 is a multi-functional agent in breast cancer cells: cytotoxic drug and inducer of sodium-iodide symporter (NIS)

(2010) N. Fortunati et al.   BREAST CANCER RESEARCH AND TREATMENT

The class-I HDAC inhibitor MGCD0103 induces apoptosis in Hodgkin lymphoma cell lines and synergizes with proteasome inhibitors by an HDAC6-independent mechanism

(2010) Daniela Buglio et al.   BRITISH JOURNAL OF HAEMATOLOGY

Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies

(2010) Bertrand Coiffier et al.   LEUKEMIA & LYMPHOMA

Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2

(2009) M. Gupta et al.   BLOOD

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma

(2009) Michael Dickinson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Clinical Studies of Histone Deacetylase Inhibitors

(2009) H. M. Prince et al.   CLINICAL CANCER RESEARCH

Histone deacetylase inhibitors: Potential in cancer therapy

(2009) P.A. Marks et al.   JOURNAL OF CELLULAR BIOCHEMISTRY

Histone Deacetylase Inhibitors in Cancer Therapy

(2009) Andrew A. Lane et al.   JOURNAL OF CLINICAL ONCOLOGY

Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines

(2008) D. Buglio et al.   BLOOD

Targeting tumor angiogenesis with histone deacetylase inhibitors

(2008) Leigh Ellis et al.   CANCER LETTERS

Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment

(2008) Bing-Hua Jiang et al.   DRUG RESISTANCE UPDATES

Glucose Metabolism as a Target of Histone Deacetylase Inhibitors

(2008) Suzanne E. Wardell et al.   MOLECULAR ENDOCRINOLOGY